<html><head></head><body><div id="history-main">
			
			<div class="d_block_inner">
				<div id="actual_explanation" style="display:none;"></div>
				<div id="global-ranks" class="stat-pane">
					<div class="explanation-topper">
						<div class="left-topper">
							<h1 class="post-title">Antiplatelet and Anticoagulant Drugs</h1>
							<h4 class="sidebar-header tax_links"><a href="https://mrcemsuccess.com/qc/9/">Pathology</a> / 
	<a href="https://mrcemsuccess.com/qc/haematology/">Haematology</a> / 
	<a href="https://mrcemsuccess.com/qc/coagulation-disorders/">Coagulation Disorders</a></h4>
						</div>
						<div class="right-topper" id="right-info">
							<h4 class="sidebar-header" id="page-numbers">Last Updated: 25th June 2019</h4>
							<button class="simplefavorite-button" data-postid="101684" data-siteid="1" data-groupid="1" data-favoritecount="633" style=""><i class="far fa-bookmark"> </i></button>						</div>
					</div>					<div id="ex-content" class="explanation-container"><h4>Antiplatelets</h4>
<ul>
<li>Aspirin irreversibly inhibits cyclo-oxygenase impairing platelet synthesis of the prostaglandin thromboxane A2, preventing platelet aggregation.</li>
<li>Dipyridamole inhibits both the reuptake of adenosine and phosphodiesterase, preventing the degradation of cAMP and thus blocking the platelet aggregation response to ADP.</li>
<li>Clopidogrel inhibits the binding of ADP to its platelet receptor, preventing platelet aggregation.</li>
<li>Abciximab, eptifibatide and tirofiban are GPIIb/IIIa inhibitors, inhibiting platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive molecules.</li>
</ul>
<p></p><div id="attachment_103237" style="width: 697px" class="wp-caption alignnone"><img aria-describedby="caption-attachment-103237" class="size-full wp-image-103237" src="/images/subjects/pathology-haematology-coagulation-disorders/Antiplatelet_effect_aspirin.jpg" alt="" width="687" height="801"><p id="caption-attachment-103237" class="wp-caption-text"><strong>Aspirin Antiplatelet Effect.</strong> (Image by Vtvu [CC BY-SA 3.0 (https://creativecommons.org/licenses/by-sa/3.0)])</p></div><p></p>
<h4>Anticoagulants</h4>
<ul>
<li>Unfractionated heparin potentiates the activity of antithrombin, which then inactivates thrombin, factor Xa and other proteases.</li>
<li>Low molecular weight heparin (LMWH) preparations inhibit factor Xa directly. Inhibition of factor Xa prevents thrombin generation and thrombus development.</li>
<li>Warfarin is a coumarin derivative that acts by inhibiting vitamin-K dependent clotting factors (factors VII, IX, X and II) as well as the anticoagulant proteins C and S.</li>
<li>Apixaban, dabigatran, edoxaban and rivaroxaban are new anticoagulants with a novel mode of action:
<ul>
<li>Apixaban, edoxaban and rivaroxaban are direct and reversible inhibitors of factor Xa.</li>
<li>Dabigatran is a reversible inhibitor of free thrombin, fibrin-bound thrombin, and thrombin-induced platelet aggregation.</li>
</ul>
</li>
</ul>
</div>
				
						
				
				</div>	
				
			
	
			</div>
			<div id="scrollup" class="active textbook"><i class="fa fa-chevron-up"></i></div>
		</div></body></html>